These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22387670)

  • 21. Metformin, hepatitis C, and insulin resistance: sufficient evidence?
    Yilmaz Y; Yonal O; Imeryuz N
    Hepatology; 2009 Dec; 50(6):2054-5; author reply 2055. PubMed ID: 19937685
    [No Abstract]   [Full Text] [Related]  

  • 22. Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4.
    Sánchez-Tapias JM; Crespo J; Diago M; Pérez R; Romero-Gómez M; Muñoz-Sánchez M
    Methods Find Exp Clin Pharmacol; 2002 Nov; 24(9):579-84. PubMed ID: 12616704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?
    Serfaty L; Fartoux L; Poupon R
    J Hepatol; 2009 Jun; 50(6):1269-71. PubMed ID: 19395115
    [No Abstract]   [Full Text] [Related]  

  • 24. Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.
    Neumann AU; Bain VG; Yoshida EM; Patel K; Pulkstenis E; Subramanian GM
    Liver Int; 2009 Oct; 29(9):1350-5. PubMed ID: 19291180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis.
    Shouval D
    J Hepatol; 2012 Feb; 56(2):303-4. PubMed ID: 22015961
    [No Abstract]   [Full Text] [Related]  

  • 26. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
    Romero-Gómez M; Diago M; Andrade RJ; Calleja JL; Salmerón J; Fernández-Rodríguez CM; Solà R; García-Samaniego J; Herrerías JM; De la Mata M; Moreno-Otero R; Nuñez O; Olveira A; Durán S; Planas R;
    Hepatology; 2009 Dec; 50(6):1702-8. PubMed ID: 19845037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The assessment of serum hepatitis C virus RNA 12 weeks after the end of treatment using TaqMan polymerase chain reaction is less relevant than after 24 weeks for predicting sustained virological response.
    Kanda T; Imazeki F; Wu S; Nakamoto S; Yokosuka O
    Hepatology; 2011 Oct; 54(4):1482; author reply 1482-3. PubMed ID: 21725991
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists].
    Hofmann WP; Bock H; Weber C; Tacke W; Pfaff R; Kihn R; Moog G; Kellner HU; Schöfer M; Frick B; Berg P; Rambow A; Friedrich-Rust M; Herrmann E; Sarrazin C; Zeuzem S
    Z Gastroenterol; 2006 Jan; 44(1):25-31. PubMed ID: 16397836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.
    Legrand-Abravanel F; Colson P; Leguillou-Guillemette H; Alric L; Ravaux I; Lunel-Fabiani F; Bouviers-Alias M; Trimoulet P; Chaix ML; Hézode C; Foucher J; Fontaine H; Roque-Afonso AM; Gassin M; Schvoerer E; Gaudy C; Roche B; Doffoël M; D'Alteroche L; Vallet S; Baazia Y; Pozzetto B; Thibault V; Nousbaum JB; Roulot D; Coppere H; Poynard T; Payan C; Izopet J
    J Med Virol; 2009 Dec; 81(12):2029-35. PubMed ID: 19856464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Sustained virological response in children with chronic hepatitis C treated with interferon alpha and ribavirin].
    Woźniakowska-Gesicka T; Kupś J; Wiśniewska-Ligier M
    Przegl Lek; 2005; 62(12):1405-8. PubMed ID: 16786760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
    Borg BB; Hoofnagle JH
    N Engl J Med; 2005 Sep; 353(11):1182-3; author reply 1182-3. PubMed ID: 16162894
    [No Abstract]   [Full Text] [Related]  

  • 36. Chronic viral hepatitis C: management update.
    Gutfreund KS; Bain VG
    CMAJ; 2000 Mar; 162(6):827-33. PubMed ID: 10750473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection.
    Miki D; Ohishi W; Ochi H; Hayes CN; Abe H; Tsuge M; Imamura M; Kamatani N; Nakamura Y; Chayama K
    J Viral Hepat; 2012 Feb; 19(2):e126-33. PubMed ID: 22239510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
    Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
    Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
    Masarone M; Persico M
    Expert Rev Anti Infect Ther; 2011 May; 9(5):535-43. PubMed ID: 21609265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Concomitant nodular goiter during IFN and ribavirin treatment of HCV: a case report].
    Lin F; Wang HF
    Zhonghua Gan Zang Bing Za Zhi; 2006 Mar; 14(3):163, 166. PubMed ID: 16700133
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.